Home Astra Signals A Late Run On BTK Inhibition
 

Keywords :   


Astra Signals A Late Run On BTK Inhibition

2015-12-14 19:08:14| Biotech - Topix.net

This morning's confirmation that AstraZeneca had made an approach to Acerta Pharma casts the spotlight on what is a private biotech that has quietly positioned itself as the most advanced developer of a BTK inhibitor after AbbVie 's blockbuster Imbruvica . Have you spotted the link? AbbVie had acquired Imbruvica through a $21bn takeover of Pharmacyclics , and Acerta was founded by Ahmed Hamdy- none other than Pharmacyclics ' ex-chief medical officer.

Tags: run late signals inhibition

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
01.11Atlantic Tropical Weather Outlook
01.11Eastern North Pacific Tropical Weather Outlook
01.11Boeing makes 38% pay rise offer in bid to end strike
01.11The house paints that promise much more than colour
01.11Eastern North Pacific Tropical Weather Outlook
01.11Atlantic Tropical Weather Outlook
01.11Technology adoption: What's on the ag tech horizon for 2025
01.11Technology adoption: What's on the ag tech horizon for 2025
More »